OEP Pharma helps North American companies advance pharmaceutical innovation and reach new markets.
A publicly traded, founder-led business, we offer our partners both financial stability and an agile, customized approach to all stages of product development and delivery.
We don't just help make and market products. We create synergy.
OEP has been the commercial partner of choice for global pharmaceutical companies for nearly 40 years.
Partners rely on our financial means, technology, and manufacturing capacity to co-develop and launch 505(b)(2)s.
Employees Globally (in 10 countries)
Out-licensing of Vancomycin capsules with PAI
OEP’s ANDA portfolio provides high-quality medications at an affordable price to patients. With our commercial partner PAI, we launched Vancomycin hydrochloride capsules, a commonly used antibiotic, into the U.S. market.
In-licensing of Multikine® cancer drug with CEL-SCI
A pioneer in cancer immunotherapy drugs, CEL-SCI has an exclusive licensing agreement with OEP for Multikine®, CEL-SCI’s lead investigational therapy. OEP invested in CEL-SCI, funded a portion of Multikine’s nine-year Phase III clinical trial, and obtained licensing rights to distribute Multikine in nine countries. The global Phase 3 study has ended and is in the data analysis stage. It is believed to be the largest head and neck cancer clinical study ever conducted, as well as the first to use immunotherapy ahead of surgery.
Co-development of 505(b)(2) ADHD Drug with DURECT
In 2009, DURECT granted OEP the development and commercialization rights to ORADUR-Methylphenidate ER Capsule (Methydur Sustained Released Capsules), its lead ORADUR-ADHD program, in 14 Asian and South Pacific countries. Together, OEP and DURECT developed a lead formulation based on clinical trial research. OEP oversaw phase III clinical trials in Taiwan, handles manufacturing, and has received, or is pursuing regulatory approvals in 14 countries, including Australia and New Zealand.